Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:

Event: Maxim Growth Summit
Date: October 22-23, 2025

Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 10-12, 2025

Event: Jefferies London Healthcare Conference
Date: November 17-20, 2025

Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Maxim, Guggenheim, and Jefferies representatives.

About Rezolute, Inc.

Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.

Rezolute Contacts:

Christen Baglaneas
[email protected]
508-272-6717

Carrie McKim
[email protected]
336-608-9706

You May Also Be Interested In

• The King Center and Divine Nine Launch Historic Fundraising Campaign to Preserve Critical History and Amplify Nonviolence365® Ahead of King100
• NCC's Executive Director and Psychometrician Bresney Fanning Assumes Presidency of the American Board of Nursing Specialties (ABNS)
• XRP Price Prediction Drowns at $1 While Pepeto Ignites a Wallet Stampede Toward